FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
The first approved disease-modifying treatment for Sanfilippo syndrome type A — a severe paediatric neurological disorder — has received FDA authorisation, according to reports citing Ultragenyx Pharmaceutical.
The US Food and Drug Administration has approved a gene therapy developed by Ultragenyx Pharmaceutical for Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA, MPS IIIA), an ultra-rare autosomal-recessive lysosomal storage disorder caused by pathogenic variants in the SGSH gene. The condition is sometimes described informally as 'childhood Alzheimer's' because of its progressive and severe neurocognitive deterioration; most affected children do not survive into adulthood.
The approval marks the first regulatory authorisation of a disease-modifying intervention for this indication. MPS IIIA results from deficiency of the enzyme N-sulphoglucosamine sulphohydrolase, leading to accumulation of heparan sulphate in the central nervous system and other tissues. Gene therapy approaches for this disorder have sought to restore functional enzyme expression via viral-vector-mediated gene delivery.
Detailed trial data, regulatory review documents, and prescribing information had not been fully available in open-access sources at time of compilation; readers should consult the FDA's approval announcement and Ultragenyx's published trial literature for primary data. The approval is reported to follow an earlier negative Phase 3 outcome for a separate Ultragenyx programme in Angelman syndrome, underscoring variability of outcomes across rare-disease gene therapy programmes.
This approval will be of immediate interest to genetic counsellors, metabolic paediatricians, and rare-disease researchers tracking the gene therapy regulatory landscape. Sanfilippo syndrome advocacy groups and affected families have been closely engaged in trial recruitment and are likely to seek information from specialist teams.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Sanfilippo syndrome type A is a rare inherited condition that affects the brain and other parts of the body. It is caused by a fault in a gene that normally produces an enzyme the body needs to break down certain large molecules. Without that enzyme, harmful material builds up in cells, particularly in the brain, leading to progressive loss of skills in childhood.
The US medicines regulator (the FDA) has approved a gene therapy made by a company called Ultragenyx for this condition. Gene therapies aim to introduce a working copy of the faulty gene into the body's cells. This is the first approved treatment specifically targeting the underlying cause of this form of Sanfilippo syndrome.
For families affected by this condition, the best source of information about whether and how any new treatment might be relevant is a clinical genetics or metabolic medicine specialist team.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-09-17STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease